Granules shares gain over 5% on U.S. FDA nod for ADHD generic capsules
The parent company’s shares closed 5.49% higher on Thursday (January 30, 2025) at ₹564.40 on the BSE. Photo: X/@GranulesIndia Generic drugmaker Granules has received final approval from the U.S. Food and Drug Administration (U.S. FDA) for its abbreviated new drug application for Attention Deficit Hyperactivity Disorder (ADHD) drug Lisdexamfetamine Dimesylate Capsules in multiple strengths. The generic…
Read More “Granules shares gain over 5% on U.S. FDA nod for ADHD generic capsules” »